Evidence map›Paper›PMID 40671381›Full record

ArticleImmunotherapy2025

Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial.

Xiaofei Zhu, Xiaolan Yin, Wenyu Liu, Chunshan Yu, Sheng Xia, Yangsen Cao, Lingong Jiang, Zhenhong Guo, Minghui Zhang, Huojun Zhang

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05783076 (Stereotactic Body Radiation Therapy and vNKT Cell Adoptive Therapy for Advanced Pancreatic Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05783076 phase2unknown statusnot on this map

Stereotactic Body Radiation Therapy and vNKT Cell Adoptive Therapy for Advanced Pancreatic Cancer: a Phase 2 Trial

TypeinterventionalSponsorChanghai HospitalRan2023 to 2025Enrolled29ConditionsPancreatic CancerArmsStereotactic body radiation therapy, adoptive cell therapy with vNKT cells
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CAR-T cell immunotherapy in rhabdomyosarcoma.Journal of translational medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaofei ZhuDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Xiaolan YinCancer Center, Shanghai 411 Hospital, China RongTong Medical Healthcare Group Co. Ltd./411 Hospital, Shanghai University, Shanghai, China.
Wenyu LiuDepartment of Hepatobiliary and Pancreatic Surgery, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Chunshan YuDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Sheng XiaDepartment of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
Yangsen CaoDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Lingong JiangDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Zhenhong GuoNational Key Laboratory of Medical Immunology & Institute of Immunology, Naval Medical University, Shanghai, China.
Minghui ZhangSchool of Medicine, Tsinghua University, Beijing, China.
Huojun ZhangDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsNovel and multimodal immunotherapy approaches are required for pancreatic cancer. A novel subset of NKT cells, called CD8+ NKT-like cells or variant NKT (vNKT) cells, which are CD8

methodsThe prescription dose of SBRT ranges from 35 to 40 Gy/5f. Transfer of allogeneic vNKT cells is initiated 1-2 weeks after SBRT. Patients receive transfusion of vNKT cells twice a month with a 12-24 h interval within 6 months after SBRT and once a month thereafter. A 12-month transfer is defined as a cycle. The primary outcome is overall survival. The secondary outcomes are progression-free survival, adverse events, and quality of life.

conclusionTherapeutic potential of SBRT plus vNKT cells may provide a novel insight into the treatment for advanced pancreatic cancer, and further investigations on the clinical benefits compared to standard chemoradiotherapy are warranted. CLINICAL

trial registrationwww.clinicaltrials.gov identifier is NCT05783076.

Indexed as

Immunotherapy, AdoptiveNatural Killer T-CellsPancreatic NeoplasmsRadiosurgeryClinical Trials, Phase II as TopicCombined Modality TherapyFemaleHumansMaleQuality of LifeTreatment OutcomeCD8+ NKT-like cellimmunotherapyNKT cellPancreatic cancerstereotactic body radiation therapy

Identifiers

PMID40671381
PMCPMC12355665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.